arrow
C

Christoph Minichsdorfer

Medical University of Vienna
H指数:15
被引数:1,013

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patients.

HER2靶向治疗与真实世界中乳腺癌患者心血管急诊就诊率增加相关。

2026-08-010
OAAI
Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency department

来自三级学术中心的真实世界证据:急诊科就诊的肿瘤患者发热性中性粒细胞减少症的临床特征、微生物学和结局

2026-05-270
OAAI
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases

曲妥珠单抗-deruxtecan治疗活动性脑转移的HER2-positive乳腺癌患者的II期TUXEDO-1试验的最终结果分析

2024-07-048
OAAI
FINAL OUTCOME ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-POSITIVE BREAST CANCER PATIENTS WITH ACTIVE BRAIN METASTASES
2024-05-020
PRE
Discovering novel targetable pathways by combining functional and multi-omic data from primary ovarian cancer samples
2023-04-040
PRE
Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial

新型冠状病毒肺炎大流行期间癌症患者口服阿奇霉素的预防性治疗 (OnCoVID): 一项随机、单盲、安慰剂对照的2期试验

2023-02-121
OAAI
NEURON-SPECIFIC ENOLASE (NSE) AND S100 SERUM LEVELS IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB-DERUXTECAN (T-DXD): A BIOMARKER ANALYSIS FROM THE TUXEDO-1 TRIAL
2022-09-050
OA
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
2022-08-08223
OAAI
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma
2022-03-2515
OAAI
Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
2021-09-0118
OAAI